A Phase 1 interventional study of Alisertib and Esomeprazole in Solid Tumors and Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-25.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.
Among the 26 studies in Lymphoma by Takeda, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 1, and was the 11th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 1997; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 36 across the 23 interventional studies, 1,000 across the 3 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Lymphoma by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
The drug tested in this study is called alisertib. Alisertib is being tested to assess the effect of a proton pump inhibitor and strong metabolic inducer on the PK of a single 50 mg dose of alisertib administered as enteric-coated tablets (ECTs).
The study enrolled 55 patients. Participants received either:
All participants were asked to take one tablet of alisertib either once or twice daily in all cycles. In Cycle 2, participants were asked to take alisertib plus either esomeprazole or rifampin.
This trial was conducted the United States. The overall time to participate in this study was 10 months. Participants made multiple visits to the clinic plus a final visit, 30 days after receiving their last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with any anticancer therapy or any agents within 4 weeks before the first dose of alisertib
- Known or intolerance to rifampin (for participants considered for the rifampin drug-drug interaction [DDI] group) or to esomeprazole (for participants considered for the esomeprazole DDI group)
Major surgery within the 14 days preceding the first dose of alisertib
- Life-threatening or uncontrolled medical illness unrelated to cancer
Prior allogeneic bone marrow or other organ transplantation
- Other severe acute or chronic medical or psychiatric condition
Please note there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1. Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2. Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles).
Drug: Alisertib · Drug: Esomeprazole
Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1. Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2. Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles).
Drug: Alisertib · Drug: Rifampin
Alisertib tablets
Also known as: MLN8237
Esomeprazole capsules
Rifampin capsules
Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without esomeprazole arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with esomeprazole arm
Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin
Time frame: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 1 for alisertib without rifampin arm; Day 8 pre-dose and at multiple time points (up to 72 hours) post-dose in Cycle 2 for alisertib with rifampin arm
Change From the Time-matched Baseline in the Individually Corrected QTc Interval (QTcI)
Time frame: Baseline, Days 1 and 10 multiple timepoints postdose (up to 24 hours) in Cycle 1
Change From the Time-matched Baseline in the Fridericia Correction of QTc (QTcF)
Time frame: Baseline, Days 1 and 10 multiple timepoints postdose (up to 24 hours) in Cycle 1
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From the first dose through 30 days after administration of the last dose of study drug (up to 328 days)
Participants took part in the study at 6 investigative sites in the United States from 25 June 2013 to 06 September 2016. Data cut-off for primary analysis was 04 August 2014.
| Milestone | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg |
|---|---|---|
| Started | 26 | 29 |
| Completed | 18 | 19 |
| Not completed | 8 | 10 |
| Withdrew: Didn't complete dosing;pk/ecg assessment | 8 | 10 |
| nmol/L | Alisertib Without Esomeprazole | Alisertib With Esomeprazole |
|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole | 1542.6 ± 357.19 | 1804.8 ± 571.89 |
| hr*nmol/L | Alisertib Without Esomeprazole | Alisertib With Esomeprazole |
|---|---|---|
| AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Esomeprazole | 20427.8 ± 6813.46 | 25094.4 ± 5574.04 |
| hr*nmol/L | Alisertib Without Esomeprazole | Alisertib With Esomeprazole |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence and Absence of Esomeprazole | 21371.4 ± 8138.55 | 26612.5 ± 6626.40 |
| hours | Alisertib Without Esomeprazole | Alisertib With Esomeprazole |
|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Esomeprazole | 4.0 (2 to 8) | 3.0 (1 to 8) |
| hours | Alisertib Without Esomeprazole | Alisertib With Esomeprazole |
|---|---|---|
| Terminal Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Esomeprazole | 16.06 ± 5.398 | 15.96 ± 5.234 |
| nmol/L | Alisertib Without Rifampin | Alisertib With Rifampin |
|---|---|---|
| Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Rifampin | 1561.4 ± 661.81 | 1581.5 ± 519.68 |
| hr*nmol/L | Alisertib Without Rifampin | Alisertib With Rifampin |
|---|---|---|
| AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib in Presence and Absence of Rifampin | 19732.0 ± 8489.24 | 9470.5 ± 2653.60 |
| hr*nmol/L | Alisertib Without Rifampin | Alisertib With Rifampin |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Alisertib in Presence or Absence of Rifampin | 17258.3 ± 6163.60 | 8955.0 ± 2389.25 |
| hours | Alisertib Without Rifampin | Alisertib With Rifampin |
|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib in Presence and Absence of Rifampin | 4.0 (1 to 23) | 2.1 (1 to 6) |
| hours | Alisertib Without Rifampin | Alisertib With Rifampin |
|---|---|---|
| Phase Elimination Half-life (T1/2) for Alisertib in Presence and Absence of Rifampin | 16.30 ± 6.608 | 8.17 ± 5.476 |
| milliseconds (msec) | Alisertib |
|---|---|
| Day 10, 0 hour postdose | -2.2 (NA to 0.99) |
| Day 1, 0.5 hour postdose | -3.7 (NA to -1.63) |
| Day 10, 0.5 hour postdose | -5.4 (NA to -2.24) |
| Day 1, 1 hour postdose | -4.5 (NA to -2.37) |
| Day 10, 1 hour postdose | -3.5 (NA to -0.4) |
| Day 1, 2 hours postdose | -4.0 (NA to -1.94) |
| Day 10, 2 hours postdose | -1.6 (NA to 1.54) |
| Day 1, 3 hours postdose | -2.5 (NA to -0.42) |
| Day 10, 3 hours postdose | -2.3 (NA to 0.89) |
| Day 1, 4 hours postdose | -1.2 (NA to 0.9) |
| Day 10, 4 hours postdose | -1.2 (NA to 1.91) |
| Day 1, 6 hours postdose | -0.9 (NA to 1.15) |
| Day 10, 6 hours postdose | -3.5 (NA to -0.33) |
| Day 1, 8 hours postdose | -0.5 (NA to 1.61) |
| Day 10, 8 hours postdose | -0.4 (NA to 2.75) |
| Day 1, 10 hours postdose | -1.5 (NA to 0.56) |
| Day 10, 10 hours postdose | -2.4 (NA to 0.73) |
| Day 1, 24 hours postdose | -3.3 (NA to -1.2) |
| milliseconds (msec) | Alisertib |
|---|---|
| Day 10, 0 hour postdose | -2.4 (NA to 0.7) |
| Day 1, 0.5 hour postdose | -3.9 (NA to -1.8) |
| Day 10, 0.5 hour postdose | -5.3 (NA to -2.19) |
| Day 1, 1 hour postdose | -4.6 (NA to -2.54) |
| Day 10, 1 hour postdose | -3.9 (NA to -0.76) |
| Day 1, 2 hours postdose | -3.5 (NA to -1.51) |
| Day 10, 2 hours postdose | -2.5 (NA to 0.63) |
| Day 1, 3 hours postdose | -2.1 (NA to -0.09) |
| Day 10, 3 hours postdose | -2.6 (NA to 0.55) |
| Day 1, 4 hours postdose | 0 (NA to 2.07) |
| Day 10, 4 hours postdose | -1.3 (NA to 1.87) |
| Day 1, 6 hours postdose | -0.5 (NA to 1.5) |
| Day 10, 6 hours postdose | -4.1 (NA to -0.92) |
| Day 1, 8 hours postdose | 0 (NA to 2.1) |
| Day 10, 8 hours postdose | -1.6 (NA to 1.54) |
| Day 1, 10 hours postdose | -1.2 (NA to 0.9) |
| Day 10, 10 hours postdose | -3.5 (NA to -0.3) |
| Day 1, 24 hours postdose | -3.8 (NA to -1.72) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| participants | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg |
|---|---|---|
| AEs | 25 | 27 |
| SAEs | 9 | 11 |
Collected over From the first dose through 30 days after administration of the last dose of study drug (up to 328 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 40 mg + Alisertib 50 mg | 1/26 (3.8%) | 9/26 (34.6%) | 25/26 (96.2%) |
| Rifampin 600 mg + Alisertib 50 mg | 3/29 (10.3%) | 11/29 (37.9%) | 25/29 (86.2%) |
| Event | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg |
|---|---|---|
| VomitingGastrointestinal disorders | 1/26 | 2/29 |
| NauseaGastrointestinal disorders | 0/26 | 2/29 |
| Deep vein thrombosisVascular disorders | 0/26 | 2/29 |
| Abdominal painGastrointestinal disorders | 1/26 | 1/29 |
| ColitisGastrointestinal disorders | 1/26 | 0/29 |
| AscitesGastrointestinal disorders | 1/26 | 0/29 |
| Urinary tract infectionInfections and infestations | 1/26 | 0/29 |
| Septic shockInfections and infestations | 1/26 | 0/29 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/26 | 0/29 |
| Cerebrovascular accidentNervous system disorders | 1/26 | 0/29 |
| Event | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/26 | 4/29 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/26 | 6/29 |
| FatigueGeneral disorders | 12/26 | 10/29 |
| StomatitisGastrointestinal disorders | 11/26 | 6/29 |
| NeutropeniaBlood and lymphatic system disorders | 10/26 | 7/29 |
| AnaemiaBlood and lymphatic system disorders | 7/26 | 8/29 |
| VomitingGastrointestinal disorders | 7/26 | 5/29 |
| NauseaGastrointestinal disorders | 7/26 | 4/29 |
| Decreased appetiteMetabolism and nutrition disorders | 7/26 | 3/29 |
| LeukopeniaBlood and lymphatic system disorders | 4/26 | 6/29 |
The safety population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| Mean | 62.2 ± 6.90 | 60.4 ± 10.58 | 61.3 ± 8.99 |
| Sex: Female, Male(Participants) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| Female | 14 | 21 | 35 |
| Male | 12 | 8 | 20 |
| Race/Ethnicity, Customized(Participants) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 22 | 24 | 46 |
| Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| White | 22 | 26 | 48 |
| Black or African American | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| American Indian or Alaska Native | 1 | 1 | 2 |
| Other | 0 | 1 | 1 |
| Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| United States | 26 | 29 | 55 |
| Height(cm) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| Mean | 166.6 ± 8.90 | 164.8 ± 9.09 | 165.7 ± 8.97 |
| Weight(kg) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| Mean | 82.07 ± 20.765 | 77.37 ± 33.801 | 79.59 ± 28.242 |
| Body Mass Index(kg/m^2) | Esomeprazole 40 mg + Alisertib 50 mg | Rifampin 600 mg + Alisertib 50 mg | Total |
|---|---|---|---|
| Mean | 29.557 ± 7.2787 | 28.026 ± 9.4175 | 28.750 ± 8.4327 |
Ran from Jun 2013 to primary completion in Aug 2014, 13 months.
Results were first posted in Mar 2019, 4 years 7 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 13 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Millennium Pharmaceuticals, Inc. →